Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Puriblood Medical Co., Ltd. (6847:TWSE), powered by AI.
Puriblood Medical Co., Ltd. is currently trading at $76.60. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Puriblood Medical Co., Ltd. on Alpha Lenz.
View Puriblood Medical Co., Ltd.'s valuation metrics on Alpha Lenz.
“Puriblood Medical Co., Ltd.'s ROE is -24.7%. Explore profitability and growth together.”
Ask for details →Puriblood Medical Co., Ltd. is a healthcare company specializing in the development and production of advanced blood purification medical devices. Founded in 2015 and headquartered in Hsinchu, Taiwan, the company focuses on creating innovative solutions for both human and animal blood transfusion needs. Key products include leukocyte reduction filters, which are designed to remove white blood cells from blood products to minimize transfusion reactions in humans, as well as specialized filters and blood bags for veterinary applications. Puriblood Medical leverages proprietary membrane technologies and holds a significant portfolio of patents, including innovations such as its Zwitterionic-bias Surface Coating Technology, aimed at improving the safety and efficiency of blood cell separation. Through collaboration with clinicians and ongoing research, the company addresses critical demands in transfusion medicine and supports sectors including hospitals, laboratories, and animal health. Puriblood Medical Co., Ltd. plays a notable role in the medical diagnostics and research industry in Taiwan, contributing to improved clinical outcomes through enhanced blood filtration and purification solutions.
“Puriblood Medical Co., Ltd.'s ROE is -24.7%. Explore profitability and growth together.”
Ask for details →Puriblood Medical Co., Ltd. (ticker: 6847) is a company listed on TWSE in the Healthcare sector (Diagnostics & Research). It has approximately 44 employees.
The current price is 76.6 with a P/E ratio of -x and P/B of -x.
ROE is -24.72% and operating margin is -40.61%. Annual revenue is $82M.